Management of Graves Thyroidal and Extrathyroidal Disease: An Update

por Kahaly, George J
Publicado 2020

TSH Receptor Antibody Functionality and Nomenclature

por Kahaly, George J., Diana, Tanja
Publicado 2017

Type 1 diabetes and associated autoimmune diseases

por Frommer, Lara, Kahaly, George J
Publicado 2020

Type 1 Diabetes and Autoimmune Thyroid Disease—The Genetic Link

por Frommer, Lara, Kahaly, George J.
Publicado 2021

Commentary: Brief report - Monoclonal antibodies illustrate the difficulties in measuring blocking TSH receptor antibodies

por Olivo, Paul D., Kahaly, George J.
Publicado 2022

Use of levothyroxine in the management of hypothyroidism: A historical perspective

por Kahaly, George J., Gottwald-Hostalek, Ulrike
Publicado 2022

Celiac Disease and Glandular Autoimmunity

por Kahaly, George J., Frommer, Lara, Schuppan, Detlef
Publicado 2018

Glucocorticoids in Graves’ orbitopathy: mechanisms of action and clinical application

por Längericht, Jan, Krämer, Irene, Kahaly, George J.
Publicado 2020

SAT459 Teprotumumab Pooled Efficacy From The European Study Sites Participating In The Phase 2, OPTIC (Phase 3) And OPTIC-X Pivotal Trials

por Kahaly, George J, Fu, Qianhong, Holt, Robert J
Publicado 2023

Thyrotropin Receptor Blocking Antibodies

por Diana, Tanja, Olivo, Paul D., Kahaly, George J.
Publicado 2018

Reply to Drs. Kiaei and Molinaro Regarding the Publication “Comparison of a Bridge Immunoassay with Two Bioassays for Thyrotropin Receptor Antibody Detection and Differentiation”...

por Allelein, Stephanie, Diana, Tanja, Schott, Matthias, Kahaly, George J.
Publicado 2020

Stimulatory Thyrotropin Receptor Antibodies Are a Biomarker for Graves’ Orbitopathy

por George, Augustine, Diana, Tanja, Längericht, Jan, Kahaly, George J.
Publicado 2021

Graves' Orbitopathy

por Hiromatsu, Yuji, Wall, Jack R., Kahaly, George J., Kakizaki, Hirohiko
Publicado 2015

Improvement of asymmetric thyroid eye disease with teprotumumab

por Ugradar, Shoaib, Wang, Yao, Mester, Tunde, Kahaly, George J, Douglas, Raymond
Publicado 2022

Teprotumumab for thyroid eye disease: early response is not required for benefit

por Ugradar, Shoaib, Wang, Yao, Mester, Tunde, Kahaly, George J., Douglas, Raymond S.
Publicado 2021

Prospective Trial of Functional Thyrotropin Receptor Antibodies in Graves Disease

por Kahaly, George J, Diana, Tanja, Kanitz, Michael, Frommer, Lara, Olivo, Paul D
Publicado 2019

OR18-01 Effect of Teprotumumab on Proptosis Reduction Across Various Demographic Sub-Groups

por Kahaly, George J, Smith, Terry J, Holt, Robert, Sile, Saba, Douglas, Raymond S
Publicado 2020

TSH/IGF-1 Receptor Cross-Talk Rapidly Activates Extracellular Signal-Regulated Kinases in Multiple Cell Types

por Krieger, Christine C., Perry, Joseph D., Morgan, Sarah J., Kahaly, George J., Gershengorn, Marvin C.
Publicado 2017

Precision Medicine in Graves’ Disease: CD40 Gene Variants Predict Clinical Response to an Anti-CD40 Monoclonal Antibody

por Faustino, Larissa C., Kahaly, George J., Frommer, Lara, Concepcion, Erlinda, Stefan-Lifshitz, Mihaela, Tomer, Yaron
Publicado 2021

OR11-4 Teprotumumab Markedly Improves Disease-related Quality of Life: Lessons From Two Randomized, Placebo-controlled Trials

por Douglas, Raymond S, Holt, Robert, Qashqai, Anahita, Sile, Saba, Smith, Terry J, Vesel, Claudia, Kahaly, George J
Publicado 2022